Early day motion tabled by primary sponsor Mohammad Yasin (Labour), on Monday, 18 July 2022, in the House of Commons. It is signed by 14 members in total.

---

Epidermolysis Bullosa

That this House welcomes the recent identification of anti-inflammatory drugs, which are already available within the NHS, that could be successful in treating Epidermolysis Bullosa (EB); notes that around 5,000 people in the UK are currently living with EB, a group of rare genetic disorders that result in fragile and blistered skin; recognises the work of DEBRA in spending £1.8 million on charitable activities in 2021, including nearly £500,000 on research projects; and further welcomes DEBRA’s drug repurposing programme, which requires the Government to commit £10 million of financial support to accelerate clinical trials and secure approved treatments for EB sufferers in the UK.

---

Secondary information

Type

Early day motion

Reference

302 

Session

2022-23

Other sponsors

Tony Lloyd

Jon Trickett

Chris Stephens

Daisy Cooper

Mick Whitley

Subjects

Drugs Dystrophic Epidermolysis Bullosa Research Association Epidermolysis bullosa

Link

View this Early day motion on edm.parliament.uk